Industry leaders used the Medicaid Drug Rebate Program summit to argue that policy changes—especially Medicare/IRA-linked reimbursement effects and Medicaid MFN dynamics—could destabilize drug development economics. BIO vice president Jack Geisser said smaller companies face immediate funding risk, citing a scenario where roughly 33% have less than one year of cash left, and warned investor hesitation could slow clinical trial starts. Community oncology advocates Nicolas Ferreyros highlighted additive pressures from physician fee declines and proposed IRA implementation cuts, arguing that shifts in site-of-service could overload hospitals—particularly in rural and underserved settings. PhRMA’s Karyn Schwartz also criticized importing international pricing controls, describing them as devaluing certain lives and compounding transparency deficits in programs like 340B. For biotech stakeholders, the immediate impact is pipeline risk: if reimbursement uncertainty changes trial economics and patient access timelines, it can alter portfolio selection, trial site decisions, and the overall probability of future approvals.